TrialClinical pharmacology in drug development2018

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Yoshishige Samukawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.